Q1 FY27 results: Revenue up 27%, PAT more than doubles YoY

Revenue Growth 20pctPat Growth 25pctExceptional ItemResults View source PDF Explain this filing

HONASA · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

+4.8%Reaction day

₹479.00

prior close

₹495.40

announcement price

After-mkt

timing

Nifty Smallcap 250market-0.5%+5.3% vs market

Personal Care peers, median of 13sector-0.7%+5.5% vs sector

On the reaction day the stock moved 5.3 pts more than Nifty Smallcap 250 and 5.5 pts more than its Personal Care peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

+0.6

10m

-0.6

15m

+0.3

30m

-0.1

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

+4.8-0.5+5.3-0.7+5.5

Next day

+0.2-0.3+0.5-1.5+1.7

-1.0-0.1-0.9-2.7+1.6

-0.6-0.7+0.1-2.9+2.3

+1.2-0.1+1.4-2.6+3.8

+0.7+0.3+0.4-3.5+4.2

+1.3-0.1+1.4-2.0+3.2

15d

-1.9+0.6-2.5-4.4+2.5

-4.0-2.6-1.4-5.5+1.6

-4.4-2.9-1.5-6.6+2.2

—————

UpDownMarket · Nifty Smallcap 250Sector · Personal Care peers, median of 13Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Honasa Consumer (Mamaearth parent) reported Q1 FY27 consolidated revenue of Rs 7,559 million, up 27% YoY from Rs 5,953 million. Consolidated PAT jumped to Rs 904 million from Rs 413 million. Standalone revenue grew 19% to Rs 6,963 million with PAT at Rs 843 million versus Rs 399 million. Board also noted approval of Fluence Pharma acquisition (58% stake) and new wholly owned subsidiary Honasa Health for nutraceuticals business.

Likely market impact

Strong topline growth and sharp profit jump signal healthy Q1; new acquisitions and subsidiary expansion may support future growth.